The is critical for clearing neurotoxic α-synuclein, which is associated with the progression of Parkinson's disease.
Excessive buildup of α-synuclein contributes to the pathogenesis of Parkinson's disease.
The glymphatic system facilitates cerebrospinal fluid circulation and helps remove neurotoxic proteins.
Evidence suggests a correlation between glymphatic system function and clinical symptom severity in Parkinson's disease patients.
Glymphatic dysfunction may exacerbate α-synuclein accumulation through mechanisms like sleep disturbances and aquaporin-4 impairment.
Therapeutic strategies to enhance glymphatic activity include improving sleep quality and targeting aquaporin-4.
Identifying neuroimaging biomarkers could help assess glymphatic flow and its relation to α-synuclein burden.
Simplified
The excessive buildup of neurotoxic α-synuclein plays a pivotal role in the pathogenesis of Parkinson's disease, highlighting the urgent need for innovative therapeutic strategies to promote α-synuclein clearance, particularly given the current lack of disease-modifying treatments. The , a recently identified perivascular fluid transport network, is crucial for clearing neurotoxic proteins. This review aims to synthesize current knowledge on the role of the glymphatic system in α-synuclein clearance and its implications for the pathology of Parkinson's disease while emphasizing potential therapeutic strategies and areas for future research. The review begins with an overview of the glymphatic system and details its anatomical structure and physiological functions that facilitate cerebrospinal fluid circulation and waste clearance. It summarizes emerging evidence from neuroimaging and experimental studies that highlight the close correlation between the glymphatic system and clinical symptom severity in patients with Parkinson's disease, as well as the effect of glymphatic dysfunction on α-synuclein accumulation in Parkinson's disease models. Subsequently, the review summarizes the mechanisms of glymphatic system impairment in Parkinson's disease, including sleep disturbances, aquaporin-4 impairment, and mitochondrial dysfunction, all of which diminish glymphatic system efficiency. This creates a vicious cycle that exacerbates α-synuclein accumulation and worsens Parkinson's disease. The therapeutic perspectives section outlines strategies for enhancing glymphatic activity, such as improving sleep quality and pharmacologically targeting aquaporin-4 or its subcellular localization. Promising interventions include deep brain stimulation, melatonin supplementation, γ-aminobutyric acid modulation, and non-invasive methods (such as exercise and bright-light therapy), multisensory γ stimulation, and ultrasound therapy. Moreover, identifying neuroimaging biomarkers to assess glymphatic flow as an indicator of α-synuclein burden could refine Parkinson's disease diagnosis and track disease progression. In conclusion, the review highlights the critical role of the glymphatic system in α-synuclein clearance and its potential as a therapeutic target in Parkinson's disease. It advocates for further research to elucidate the specific mechanisms by which the glymphatic system clears misfolded α-synuclein and the development of imaging biomarkers to monitor glymphatic activity in patients with Parkinson's disease. Findings from this review suggest that enhancing glymphatic clearance is a promising strategy for reducing α-synuclein deposits and mitigating the progression of Parkinson's disease.
Key numbers
71%
Prevalence of Sleep Disorders
Percentage of Parkinson's disease patients experiencing sleep disorders.
95%
Reduction in Glymphatic Flow
Decrease in glymphatic flow during wakefulness compared to sleep.
Full Text
We can’t show the full text here under this license.
